Anita Pramoda Sells 34,000 Shares of Health Catalyst (NASDAQ:HCAT) Stock

Share on StockTwits

Health Catalyst (NASDAQ:HCAT) Director Anita Pramoda sold 34,000 shares of the stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $34.18, for a total transaction of $1,162,120.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Anita Pramoda also recently made the following trade(s):

  • On Friday, August 14th, Anita Pramoda sold 4,000 shares of Health Catalyst stock. The stock was sold at an average price of $31.46, for a total transaction of $125,840.00.
  • On Wednesday, July 15th, Anita Pramoda sold 30,000 shares of Health Catalyst stock. The shares were sold at an average price of $36.20, for a total transaction of $1,086,000.00.

Shares of NASDAQ HCAT opened at $35.73 on Wednesday. The company has a current ratio of 7.91, a quick ratio of 7.91 and a debt-to-equity ratio of 0.76. Health Catalyst has a 12 month low of $17.48 and a 12 month high of $41.26. The firm has a market capitalization of $1.42 billion, a PE ratio of -12.03 and a beta of 0.77. The firm has a fifty day simple moving average of $33.41 and a two-hundred day simple moving average of $29.56.

Health Catalyst (NASDAQ:HCAT) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.15) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.39) by $0.24. Health Catalyst had a negative net margin of 46.91% and a negative return on equity of 20.74%. The business had revenue of $43.26 million during the quarter, compared to analyst estimates of $42.19 million. During the same period in the prior year, the business earned ($0.21) EPS. The company’s revenue for the quarter was up 17.5% on a year-over-year basis. On average, sell-side analysts predict that Health Catalyst will post -1.68 earnings per share for the current year.

A number of equities research analysts have recently issued reports on the stock. SVB Leerink upped their price objective on shares of Health Catalyst from $32.00 to $40.00 and gave the company an “outperform” rating in a research note on Friday, July 10th. Stifel Nicolaus upped their price objective on shares of Health Catalyst from $36.00 to $37.00 and gave the company a “buy” rating in a research note on Wednesday, August 12th. Truist Financial upped their price objective on shares of Health Catalyst from $36.00 to $43.00 in a research note on Wednesday, August 12th. BidaskClub raised shares of Health Catalyst from a “hold” rating to a “buy” rating in a research note on Tuesday. Finally, Guggenheim increased their price target on shares of Health Catalyst from $33.00 to $37.00 in a research report on Tuesday, August 18th. One research analyst has rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $38.82.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. boosted its holdings in shares of Health Catalyst by 131.0% during the 2nd quarter. Vanguard Group Inc. now owns 2,062,909 shares of the company’s stock valued at $60,176,000 after acquiring an additional 1,170,020 shares during the last quarter. Janus Henderson Group PLC boosted its holdings in shares of Health Catalyst by 720.4% during the 1st quarter. Janus Henderson Group PLC now owns 1,178,704 shares of the company’s stock valued at $30,823,000 after acquiring an additional 1,035,031 shares during the last quarter. Wells Fargo & Company MN boosted its holdings in shares of Health Catalyst by 503.2% during the 1st quarter. Wells Fargo & Company MN now owns 1,111,455 shares of the company’s stock valued at $29,064,000 after acquiring an additional 927,194 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Health Catalyst by 387.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 753,347 shares of the company’s stock valued at $21,975,000 after acquiring an additional 598,897 shares during the last quarter. Finally, Clearbridge Investments LLC boosted its holdings in shares of Health Catalyst by 120.4% during the 1st quarter. Clearbridge Investments LLC now owns 1,011,568 shares of the company’s stock valued at $26,453,000 after acquiring an additional 552,536 shares during the last quarter. Institutional investors and hedge funds own 85.53% of the company’s stock.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations primarily in the United States. The company operates through two segments, Technology and Professional services. Its products include cloud-based data platform, analytics software, and professional services.

Further Reading: How does the Beige Book influence monetary policy?

Insider Buying and Selling by Quarter for Health Catalyst (NASDAQ:HCAT)

Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

AQR Capital Management LLC Has $4.10 Million Stake in Cathay General Bancorp
AQR Capital Management LLC Has $4.10 Million Stake in Cathay General Bancorp
Tandem Diabetes Care Inc  Shares Purchased by AQR Capital Management LLC
Tandem Diabetes Care Inc Shares Purchased by AQR Capital Management LLC
Vista Outdoor Inc  Position Lifted by AQR Capital Management LLC
Vista Outdoor Inc Position Lifted by AQR Capital Management LLC
MYR Group Inc  Shares Sold by AQR Capital Management LLC
MYR Group Inc Shares Sold by AQR Capital Management LLC
Virtus Investment Partners Inc  Shares Sold by AQR Capital Management LLC
Virtus Investment Partners Inc Shares Sold by AQR Capital Management LLC
AQR Capital Management LLC Lowers Position in Nextgen Healthcare Inc
AQR Capital Management LLC Lowers Position in Nextgen Healthcare Inc


 
© 2006-2020 Zolmax.